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ABSTRACT 
Non-steroidal anti-inflammatory drugs (NSAIDs) including both traditional non-selective NSAIDs and the selective cyclooxygenase (COX)-2 
inhibitors, are widely used for their anti-inflammatory and analgesic effects. NSAIDs are a necessary choice in pain management because of the 
integrated role of the COX path way in the generation of inflammation and in the biochemical recognition of pain. NSAIDs are the competitive 
inhibitors of cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins (PGs). 
Their use is associated with the side effects such as gastrointestinal and renal toxicity. They are the most commonly employed first line drugs for 
all these conditions and many others-like musculoskeletal trauma, minor aches and pains, and dysmenorrhoea. The therapeutic anti-
inflammatory action of NSAIDs is produced by the inhibition of COX-2, while the undesired side effects arise from inhibition of COX-1 activity. 
Thus, it was though those more selective COX-2 inhibitors would have reduced side effects. Based upon a number of selective COX-2 inhibitors 
(Rofecoxib, Celecoxib etc.) were developed as safer NSAIDs with improved gastric safety profile. Several newer applications like prophylaxis of 
stroke with aspirin are now common place. Use of these drugs for the prophylaxis of conditions like Alzheimer’s disease and colorectal cancer is 
being evaluated. Unfortunately, they have several toxicities ranging from minor heartburn to severe gastrointestinal haemorrhage and 
perforation. Therefore, newer NSAIDs have been introduced in recent years to circumvent this problem. In preliminary studies, these have 
shown better safety, efficacy, and tolerability but the full spectrum of adverse reactions of these drugs is yet to be fully known. This review can 
be used for further research as well as clinical purpose. 
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Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a 
diverse group of compounds with similar biological 
capabilities: all NSAIDs reduce or eliminate the erythema, 
swelling, elevated temperature and pain caused by a variety 
of inflammatory stimuli. The mechanisms of action of NSAIDs 
have not yet been fully elucidated, but evidence suggests that 
their anti- inflammatory effects are primarily achieved 
through inhibiting prostaglandin production. This mode of 
action is common to all NSAIDs1. The cyclooxygenase 
enzyme was first identified as the therapeutic target of 
NSAIDs by Vane in 1971, showing that these anti-
inflammatory substances block the biosynthesis of 
prostaglandins (PGs) that contribute to a variety of 
physiological and pathophysiological functions2. The most 
prominent NSAIDs are aspirin, and naproxen, all available 
over the countries in most countries. Paracetamol 
(acetaminophen) is generally not considered an NSAID 
because it has only little anti-inflammatory activity. It treats 
pain mainly by blocking COX-2 mostly in the central nervous 
system, but not much in the rest of the body. Cyclooxygenase 
(COX) inhibitors, commonly called non steroidal anti-
inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, 
and naproxen, have anti-inflammatory and analgesic/ 
antipyretic properties across a wide range of dosing 
regimens. Prescription-strength NSAIDs are effective for 
relief of chronic musculoskeletal pain and inflammation in 
conditions such as rheumatoid arthritis (RA) or 
osteoarthritis (OA). Lower, Over-The-Counter (OTC) doses of 
NSAIDs are effective for short-term (e.g. ≤10 days) relief of 
minor aches and pains due to headache, toothache, backache, 
menstrual cramps, common cold, muscular aches, and 
arthritis. NSAIDs taken at OTC doses can also be effective at 
relieving painful episodes in patients with chronic diseases 
such as OA. Ibuprofen is an NSAID with a long history of safe 
and effective use at both prescription (maximum 2,400–
3,200 mg/d) and OTC (<1,200 mg/d) doses3. Single-dose 
studies using OTC doses have confirmed that ibuprofen (400 
mg) provides superior analgesic efficacy to acetaminophen 
(1,000 mg). 
All NSAIDs inhibit COX, an enzyme that converts arachidonic 
acid to prostaglandins, thereby mediating pain, 
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inflammation, and fever. In the process, prostaglandin H2 is 
converted to five primary prostaglandins, including 
thromboxane A2 (which stimulates platelet aggregation and 
blood clot formation) in platelets and prostacyclin (a 
vasodilator that inhibits platelet aggregation) in the 
endothelium. Two COX isoenzymes (COX-1 and COX-2) are 
commonly recognized. In general, COX-1 is constitutively 
expressed and is involved in gastroprotection from stomach 
acid and in thromboxane formation by platelets. COX-2 is 
inducible by inflammatory mediators in a wide range of 
tissues and has been associated with inflammation; however, 
it may also be constitutively expressed, where it contributes 
to renal physiology, reproductive function, bone resorption, 
and neurotransmission. 
Classification 
 Non-selective COX inhibitors: 
- Salisylates : Aspirin, sodium salisylate 
- Propionic acid derivatives: Ibuprofen, naproxen, 
ketoprofen, flubiprofen 
- Anthranilic acid derivatives: Mephanamic acid, 
meclofenamic acid 
- Aryl-acetic derivatives: Diclofenac, aceclofenac 
- Oxicams: Piroxicam, tenoxicam 
- Pyrolo-pyrol derivatives: Ketorolac 
- Indole derivatives: Indomethacin 
- Pyrozolone derivatives: Phenylbutazone, 
oxyphenbutazone 
 Preferentical COX-2 inhibitiors: Nimesulide, meloxicam, 
nabumetone 
 Selective COX-2 inhibitors: Celecoxib, rofecoxib, 
etoricoxib, parecoxib 
 Analgesics-anti-pyretics: 
- Paraminophenol: Paracetamol 
- Pyrozolone derivative: Metamizol, propiphenazone 
 
Biological roles of prostaglandins 
Prostaglandins (PGs) are hormone-like bioactive substances 
mediating autocrine and paracrine signaling over the short 
distances and are involved in many physiological and 
pathological processes. They act via high-affinity G-protein-
coupled receptors: four EP receptors for PGE2 termed EP1-
EP4, IP receptor for prostacycline, DP receptor for PGD2, FP 
receptor for PGF2α. These receptors are linked to the 
different signal transduction pathways3. Once a prostanoid is 
formed, it exits the cell and then interacts with G protein-
coupled receptors, either on the parent cell or on closely 
neighboring cells to modulate the second messenger levels4. 
Although their tissue distribution depends on the cellular 
enzymatic material, prostanoids are involved in a very broad 
range of physiological and pathophysiological responses5. 
Enzymatic structure 
The COX isoenzymes are membrane-bound enzymes in the 
endoplasmic reticulum (ER). The three dimensional 
structure of the ovine COX-1 was first reported in 1994 and 
the crystal structures of human and murine COX-2 quickly 
followed. COX functions as a homodimer and attempts to 
create monomeric species which have yielded only inactive 
enzyme. The crystal structures of the COX isoforms are quite 
structurally homologous and consistent with a high sequence 
identity (ca. 60%); the overall structures of COX-1 and COX-2 
are highly conserved. The COX monomer consists of three 
structural domains: an N-terminal epidermal growth factor 
(EGF)-like domain, a membrane binding domain (MBD) of 
about 48 amino acids in length which anchors the protein to 
one leaflet of the lipid bilayer, and a large C-terminal 
globular catalytic domain with the COX active site which 
accommodates the substrate or the inhibitors and the 
peroxidase one which contains the heme cofactor. These 
sites are distinct but functionally and structurally 
interconnected6.
 
 
Figure 1: General mechanism of NSAIDs 
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Mechanism of action 
COX enzymes (i.e., COX-1 and COX-2) catalyze the conversion 
of arachidonic acid into prostaglandin (PG) G2, an unstable 
intermediate that is rapidly converted to PGH2. 
Subsequently, PGH2 is metabolized into different 
structurally-related PGs, including PGE2, PGD2, PGF2, PGI2 
and thromboxane (TX)A27. COX-1 is constitutively expressed 
in mammalian tissues, and COX-1-derived PGs are essential 
for physiological functions, although studies in experimental 
models of CRC have suggested that COX-1 could exert tumor-
promoting effects8. In contrast, COX-2 is inducible by 
inflammatory cytokines, growth factors and tumor 
promoters in several cell types. Upregulation of COX-2 
expression is seen in 40–50% of human colorectal adenomas 
and in 80–90% of carcinomas and results in enhanced PG 
production9. COX-2 plays a pivotal role in tumor initiation, 
promotion and progression by increasing the production of 
(1) reactive oxygen species, (2) PGE2 and other PGs that 
promote cell proliferation, (3) vascular endothelial growth 
factor and platelet-derived growth factor and (4) matrix 
metalloproteinases. COX-2 also controls the expression of 
both pro- and anti-apoptotic proteins and restrains the 
proliferation of immune cells with anti-neoplastic activity. 
Among the NSAIDs, aspirin is the only drug that is able to 
permanently inhibit COX-1 and COX-2 activity. At anti-
platelet therapeutic doses (75–100 mg daily), aspirin is up to 
100-fold more potent in inhibiting platelet COX-1 than 
monocyte COX-210. 
The analgesic and anti-inflammatory actions of NSAIDs 
including COX-2 selective inhibitors are due to their effective 
inhibition of prostaglandin synthesis catalysed by the COX-2 
isoenzyme (Figure 2). This isoenzyme is massively up-
regulated in inflammatory states such as rheumatoid 
arthritis, so inhibiting it reduces inflammation. Aspirin and 
the non-selective NSAIDs inhibit COX-1 and COX-2 
isoenzyme. The COX-1 isoenzyme is involved in the synthesis 
of prostaglandins. These prostaglandins protect the gastric 
mucosa from ulceration and participate in platelet 
aggregation via the prostaglandin derivative, thromboxane 
A2. Inhibition of COX-1 has been strongly implicated in the 
gastric ulceration and bleeding induced by the non-selective 
NSAIDs. 
In platelets, inhibition of COX-1 leads to inhibition of 
thromboxane A2 synthesis. This very effectively inhibits 
platelet aggregation. Low-dose aspirin irreversibly inhibits 
platelet aggregation via this mechanism and is therefore 
widely employed as prophylaxis against thrombotic 
cardiovascular disease. At therapeutic doses, COX-2 selective 
inhibitors have little effect on the COX-1 enzyme, so they do 
not inhibit platelet aggregation. 
 
 
Figure 2: MOA 
Naproxen 
Naproxen is a non-steroidal anti-inflammatory drug (NSAID). 
It works by reducing hormones that cause inflammation and 
pain in the body. Naproxen is used to treat pain or 
inflammation caused by conditions such as arthritis, 
ankylosing spondylitis, tendinitis, bursitis, gout or menstrual 
cramps. Naproxen sodium is an anti-inflammatory agent 
with analgesic and anti-pyretic properties. Both the acid and 
its sodium salt are used in the treatment of rheumatoid 
arthritis and other rheumatic or musculoskeletal disorders, 
dysmenorrhea, and acute gout. Naproxen Sodium is 
the sodium salt form of naproxen, a member of the aryl-
acetic acid group of non-steroidal anti-inflammatory drugs 
(NSAIDs) with anti-inflammatory analgesic and antipyretic 
properties. Naproxen sodium reversibly and competitively 
inhibits cyclooxygenases (COX), thereby blocking the 
conversion of arachidonic acid to pro-inflammatory 
prostaglandins. This inhibits the formation of prostaglandins 
that are involved in pain, inflammation and fever. The over-
the-counter (OTC) use of naproxen is expected to pose 
minimal cardiovascular risk; however, the benefit–risk ratio 
and appropriate use should be considered at an individual 
patient level, particularly to assess underlying conditions 
that may increase the risk of events. Likewise, regulatory 
authorities should revisit label information periodically to 
ensure labeling reflects the current understanding of 
benefits and risks. Musculoskeletal aches and pains are one 
of the most common medical complaints around the world, 
and increasing life expectancies are driving an increased 
incidence of degenerative joint disease, burdening patients 
and healthcare systems11. Naproxen binds reversibly with 
COX-1 and COX-2 to exert its effects but has an increased 
selectivity for COX-1 inhibition, which is fivefold greater than 
the level of COX-2 inhibition 12. Naproxen reaches peak 
plasma concentrations between 2 and 4 h (naproxen 
sodium C max at 1–2 h) and has a half-life of 12–17 h13. 
Naproxen is a highly effective analgesic, and its long half-life 
provides consistent blood levels and efficacy, making it a 
choice comparator in many clinical trials. Naproxen's 
medical uses are related to its mechanism of action as an 
anti-inflammatory compound. Naproxen is used to treat a 
variety of inflammatory conditions and symptoms that are 
due to excessive inflammation such as pain and fever 
(naproxen has fever-reducing, or anti-pyretic properties in 
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addition to its anti-inflammatory activity). Notably, not all 
medications that reduce fever are anti-inflammatory 
compound Inflammatory sources of pain that may respond 
to naproxen's anti-inflammatory activity are conditions such 
as migraine, osteoarthritis kidney stones, rheumatoid 
arthritis, psoriatic arthritis, gout, ankylosing spondylitis, 
menstrual cramps tendinitis and bursitis. 
Side effects 
Naproxen side effects may include: 
 Indigestion, heartburn, stomach pain, nausea; 
 Headache, dizziness, drowsiness; 
 Bruising, itching, rash; 
 Swelling; or 
 Ringing in your ears 
 Swelling or rapid weight gain; 
 The first sign of any skin rash, no matter how mild; 
 Signs of stomach bleeding - bloody or tarry stools, 
coughing up blood or vomit that looks like coffee 
grounds; 
 Liver problems - nausea, upper stomach pain, itching, 
tired feeling, flu-like symptoms, loss of appetite, dark 
urine, clay-colored stools, jaundice (yellowing of the 
skin or eyes); 
 Kidney problems - little or no urinating, painful or 
difficult urination, swelling in your feet or ankles, feeling 
tired or short of breath; 
 Low red blood cells (anemia) - pale skin, feeling light-
headed or short of breath, rapid heart rate, trouble 
concentrating; or 
 Severe skin reaction - fever, sore throat, swelling in your 
face or tongue, burning in your eyes, skin pain followed 
by a red or purple skin rash that spreads (especially in 
the face or upper body) and causes blistering and 
peeling. 
Adverse drug reactions of naproxen 
Allergic reactions: If you have had a reaction to 
acetylsalicylic acid (ASA) or other NSAIDs (e.g., ibuprofen, 
ketoprofen, ketorolac) that included a runny nose, itchy skin 
rash, nasal polyps, or shortness of breath and wheezing, you 
should not take this medication. If you experience symptoms 
of a severe allergic reaction (e.g., hives; difficulty breathing; 
wheezing; swelling of the face, tongue, or throat). 
Aseptic meningitis: This medication can rarely cause 
symptoms of aseptic meningitis (inflammation or swelling of 
the membranes around the brain and spinal cord that is not 
caused by bacteria). If you have an autoimmune condition 
(e.g., systemic lupus erythematosus, mixed connective tissue 
disease), Symptoms such as stiff neck, severe headache, 
nausea, vomiting, fever, or changes in consciousness. 
Bladder problems: This medication may cause bladder 
pain, painful or difficult urination, or increased frequency of 
urination. 
Blood clotting: This medication may reduce the ability of 
the blood to clot. If you are taking anticoagulants (e.g., 
warfarin, heparin) or have hemophilia or other blood 
disorders (e.g., low platelets), discuss with your doctor how 
this medication may affect your medical condition, how your 
medical condition may affect the dosing and effectiveness of 
this medication. 
Drowsiness/reduced alertness: As with other NSAIDs, 
naproxen sodium can cause drowsiness, dizziness, and 
blurred vision. Avoid driving and other activities that require 
alertness and concentration until you determine the effect 
this medication has on you. 
Fluid and electrolyte balance: NSAIDs such as naproxen 
sodium can cause fluid retention and edema (swelling). This 
can lead to high blood pressure or worsening of heart failure. 
If you have heart failure or high blood pressure. Naproxen 
sodium may also cause high blood potassium levels. If you 
are a senior; have diabetes or kidney failure; or are taking 
beta-blockers (e.g., metoprolol, atenolol), angiotensin 
converting enzyme (ACE) inhibitors (e.g., ramipril, enalapril), 
or some diuretics (e.g., triamterene, amiloride), you are more 
at risk of high blood potassium.  
Heart attack and stroke: This medication may be 
associated with an increased risk of heart attack and stroke. 
The risk is increased with higher total daily doses and taking 
the medication over long periods of time. If you have a 
history of heart disease (e.g., heart attack, stroke, heart 
failure) or have risk factors for heart disease (e.g., high blood 
pressure, high cholesterol, diabetes, smoking, kidney 
disease) discuss with your doctor how this medication may 
affect your medical condition, how your medical condition 
may affect the dosing and effectiveness of this medication, 
and whether any special monitoring is needed. 
Kidney function: Long-term use of naproxen sodium may 
lead to kidney problems. If you have kidney problems, liver 
disease, or heart failure; or are dehydrated, on a salt 
restricted diet, or are a senior, you have an increased risk for 
kidney problems while taking this medication. If you are 
taking medications such as diuretics (e.g., hydrochloro 
thiazide, triamterene, indapamide), ACE inhibitors (e.g., 
enalapril, ramipril), angiotensin receptor blockers (e.g., 
valsartan, candesartan), or cyclosporine, you are also at an 
increased risk. 
Liver problems: Rarely, this medication causes liver 
problems. If you have reduced liver function 
Skin reactions: This medication can cause skin reactions, 
some of which may be severe. If you experience a skin rash, 
especially where the skin is blistering or peeling, This 
medication may make your skin more sensitive to sunlight 
(including sunlamps) and may cause sunburn, skin blisters, 
and skin redness, itching or discolouration.  
Ulcers or bleeding in the stomach or intestines: Naproxen 
sodium can cause stomach ulcers, perforation (holes), and 
bleeding from the stomach. These complications can occur at 
any time without warning and are sometimes severe enough 
to require immediate medical attention. The risk of ulcers 
and bleeding are increased if you are taking higher doses of 
this medication for longer periods of time. Other factors that 
increase the risk of these complications include drinking 
excessive amounts of alcohol, increased age, smoking, poor 
health, H pylori infection, and taking certain medications 
(e.g., warfarin, ASA, clopidogrel, prednisone, citalopram, 
fluoxetine, paroxetine, sertraline). If you currently have 
ulcers in the stomach or intestines that are bleeding, or have 
an inflammatory bowel disease (e.g., Crohn's disease, 
ulcerative colitis) ,  
Pregnancy: This medication should not be used during the 
third trimester (last 3 months) of pregnancy. This 
medication should not be used during the first and second 
trimester (first 6 months) of pregnancy unless the benefits 
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outweigh the risks. This medication may reduce your ability 
to become pregnant.  
Breast-feeding: You should not use this medication if you 
are breast- feeding. 
Adverse drug reactions of NSAIDS 
ADRs associated with NSAIDs primarily manifest in 
gastrointestinal (GI), cardiovascular (CV), and renal sites. 
GI effects 
GI complications are well-recognized risks of NSAIDs as a 
class and vary by the respective NSAID used as well as by 
dose14. Like Aspirin increases bleeding risk, even at low 
cardioprotective doses. In terms of non-selective NSAIDs, a 
meta-analysis of data from three retrospective case-control 
studies found that ibuprofen had the lowest odds ratio (OR) 
for development of GI bleeding versus diclofenac, naproxen, 
piroxicam, and indomethacin, but that the OR increases with 
dose level for each agent15,16. Ibuprofen was noted to 
produce significantly fewer overall GI AEs vs acetaminophen. 
In this study, a significant AE was defined as any event that 
was serious, severe, or moderate; necessitated a second 
physician consultation; led to treatment discontinuation; or 
was of missing intensity. The Paracetamol, Aspirin, and 
Ibuprofen New Tolerability (PAIN) study (N=8,677) assessed 
the frequency of significant adverse events (AEs) associated 
with OTC analgesic dosing in patients with acute pain. 
In this study, a significant AE was defined as any event that 
was serious, severe, or moderate; necessitated a second 
physician consultation; led to treatment discontinuation; or 
was of missing intensity. The PAIN study demonstrated that 
OTC ibuprofen (≤1,200 mg/d) was similar to acetaminophen 
(≤3,000 mg/d) in terms of the incidence of significant AEs 
(13.7% vs 14.5%, respectively), but that statistically 
significantly fewer such events occurred with ibuprofen in 
comparison with aspirin during 1–7 days of treatment17. As 
expected, rates of GI AEs were significantly lower in patients 
receiving OTC doses of ibuprofen versus aspirin (4.0% vs 
7.1%; P<0.001), and interestingly, ibuprofen was noted to 
produce significantly fewer overall GI AEs vs acetaminophen 
(5.3%; P=0.025). The PAIN study also identified numerous 
factors associated with increased risk of AEs, including 
female sex, older age, height ≤160 cm, use of the analgesic for 
musculoskeletal pain (vs menstrual cramps, sore throat, 
toothache, or fever), concomitant use of prohibited 
medications, and increasing number of concomitant 
medications18. Concomitant medications also influence the 
risk of GI events among NSAID users. The risk of upper GI 
events is increased when non-aspirin NSAIDs are combined 
with aspirin, but this increase in risk may be ameliorated 
when NSAIDs are used concurrently with ulcer-healing drugs 
(i.e., proton pump inhibitors)19. 
CV risk  
All non-aspirin NSAIDs may be associated with a potential 
increase in CV thrombotic risk. The risk of heart attack or 
stroke may increase if you use more than directed or for 
longer than directed 20,21. Hence there is no period of latency 
for CV thrombotic risk, and therefore, patients should take 
the lowest dose of NSAIDs for the shortest period of time 
possible. There are few data on actual CV risk with NSAID 
use at OTC doses, but risk is likely to be small, especially in 
younger patients who have few CV risk factors. It has been 
hypothesized that the increase in CV risk among NSAID users 
stems from increased blood pressure (BP) due to COX-2 
inhibition in the kidneys – an effect that has not been 
observed with OTC doses 22,23. 
 
Renal 
All NSAIDs can alter renal function by inhibiting COX-1 
(which regulates renal hemodynamics and glomerular 
filtration) and/or COX-2 (which mediates salt and water 
excretion) expressed in the kidneys. Uncommon, but 
concerning, renal syndromes caused by nonselective NSAIDs 
include sodium retention, peripheral edema, increased BP 
and weight, congestive heart failure (rare), hyperkalemia, 
and acute renal failure. Risk factors include preexisting 
severe hepatic or renal dysfunction, nephrotic syndrome 
with high-level proteinuria, older age, diabetes, 
hypertension, and congestive heart failure24. Furthermore, 
individuals experiencing renal stress (e.g., dehydration) from 
exercise in hot environments may be at a small increased 
risk for acute renal failure with ibuprofen25. NSAIDs may 
lessen response to diuretics and worsen renal insufficiency 
associated with use of angiotensin-converting enzyme 
inhibitors (ACEIs) and angiotensin II receptor blockers 
(ARBs). However, a study of OTC analgesics in elderly 
patients with diuretic-treated hypertension and mild renal 
insufficiency found no significant impact of ibuprofen on 
creatinine clearance nor on blood urea nitrogen, serum 
creatinine, sodium, or potassium levels. Aldosterone 
antagonists (e.g., Spiranolactone) are associated with an 
increased risk of GI bleeding and possibly impaired healing 
of gastric or duodenal erosions 26,27. Thus, risk of GI bleeding 
in patients taking these agents may be further increased 
when NSAIDs are used concomitantly. Patients treated long 
term with aldosterone antagonists should be informed of the 
risk of upper GI bleeding and perhaps warned of the risk of 
using OTC NSAIDs long term. It found that prescription of 
ibuprofen and its administration decreased clearance of 
furosemide and increased urine sodium excretion. Topical 
diclofenac had no effect on furosemide pharmacokinetics or 
pharmacodynamics, and oral diclofenac compared with 
furosemide alone decreased urine output, but neither 
formulation was associated with alterations in BP. 
Anti-thrombotics 
NSAIDs are not prone to a direct pharmacodynamic 
interaction with anticoagulants such as warfarin; however, 
concurrent use of NSAIDs and anti-thrombotics may further 
increase the likelihood of GI bleeding. Metabolism of S-
warfarin, the most clinically relevant warfarin isomer, occurs 
via CYP2C9.Ibuprofen and other NSAIDs are also substrates 
of CYP2C9and may thus increase anticoagulant activity by 
delaying S-warfarin metabolism. Therefore, it may be 
prudent to avoid prescription-strength NSAIDs in patients 
receiving warfarin28. In contrast, one of the metabolites of 
acetaminophen (N-acetyl-para-benzoquinone-imine) 
interferes with enzymes involved in the vitamin K cycle, 
which ultimately can lead to reduction in synthesis of 
clotting factors and excessive anticoagulation29. Even with 
short-term use, acetaminophen given concurrently with 
anticoagulants may increase international normalized ratio 
(INR), implying an increase in bleeding risk and 
necessitating close INR monitoring and possible warfarin 
dosage adjustments30. Aspirin Co-administration of aspirin 
and most NSAIDs (other than diclofenac and ketorolac) can 
lead to pharmacodynamic DDIs resulting from competition 
for access to the acetylation site of platelet-expressed COX-1. 
NSAID-driven reversible, transient inhibition of platelet 
aggregation blocks aspirin’s irreversible inhibition, thereby 
potentially allowing clot formation. This NSAID-driven effect 
on aspirin is of particular concern in individuals at high CV 
risk who take low-dose aspirin daily to reduce the risk of a 
thrombotic event. Ibuprofen should be avoided in patients 
with known or suspected aspirin-sensitive asthma. Patients 
should be counseled to limit their use of OTC NSAIDs and to 
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avoid acetaminophen while on anticoagulant therapy, the 
former because of the increased risk of GI bleeding with 
NSAIDs, however small, and the latter because of the direct 
interaction that would increase the risk of all-site bleeding31. 
Anti-depressants 
Anti-depressants are psychiatric medications used to 
alleviate mood and anxiety disorders. Some antidepressants 
may be associated with an increased risk for bleeding, which 
may be additively enhanced by co-administration of NSAIDs. 
Selective serotonin reuptake inhibitors (SSRIs) increase 
bleeding risk by inhibiting platelet adhesion and 
function. Co-administration of NSAIDs in patients taking 
SSRIs can substantially increase the risk of bleeding32. 
Several mechanisms may account for the interaction 
between SSRIs and NSAIDs: 1) Both classes inhibit platelet 
aggregation and function but via different mechanisms;33. 2) 
A pharmacokinetic interaction in which some SSRIs inhibit 
CYP2C9, an enzyme responsible for the metabolism of some 
NSAIDs (e.g., ibuprofen and diclofenac); 34, or 3) Independent 
effects in which SSRIs increase symptoms and bleeding via 
an independent mechanism without any direct 
pharmacokinetic interaction (e.g., by increasing gastric acid 
secretion). Tricyclic anti-depressants (TCAs) do not 
substantially inhibit CYP2C9. In the Dutch cohort study, in 
contrast to the tenfold increase in risk when NSAIDs are 
added to SSRIs, patients receiving TCAs plus an NSAID 
experienced a more modest increase in GI events34. 
Anti-rheumatics/chemotherapy 
Methotrexate is an anti-metabolite used at high doses as a 
chemotherapeutic and at low doses for treatment of 
psoriasis and RA 35. Several NSAIDs, including prescription 
ibuprofen and naproxen, have been found to reduce renal 
clearance of Methotrexate36, which could lead to toxicity 
(e.g., renal failure or pancytopenia), at least when 
Methotrexate is used at high doses. A single-case report 
speculated that daily use of an OTC ibuprofen product for 4 
weeks reduced Methotrexate excretion. Resulting 
Methotrexate accumulation caused bone marrow depletion, 
which may have contributed to Pneumocystis 
carinii pneumonia in a patient with Crohn’s disease37,38. 
Given that renal effects have also been reported with 
prescription ibuprofen monotherapy39. Patients taking high-
dose Methotrexate should avoid NSAID use, even at OTC 
doses. Additionally, caution should be exercised when 
NSAIDs are used in patients receiving low-dose 
Methotrexate. No other reports of clinically relevant DDIs 
resulting in ADRs in individuals receiving concomitant 
NSAIDs and chemotherapeutics or rheumatologic therapies 
were identified35. 
Fertility 
NSAIDs (doses not reported) were associated with an 80% 
increased risk for miscarriage with even higher risks when 
NSAIDs were taken close to the time of conception or for 
longer than 1 week. There was a trend toward increased risk 
with aspirin use but no increase in risk associated with 
acetaminophen. While data are limited, it has been 
hypothesized that NSAID use may reduce fertility and 
increase the risk of miscarriage. It may be prudent for 
women who are trying to become pregnant to avoid NSAID 
use around the time of conception40. Additionally, 
prostaglandins play an important role in maintaining the 
patency of the fetal ductus arteriosus during the third 
trimester of pregnancy41. 
 
 
Corticosteroids 
Combined use of oral corticosteroids and NSAIDs may 
increase the potential for serious GI toxicity. On further 
analysis, this increased risk was attributed to a 4.4-fold 
increased risk for peptic ulcer disease in individuals who had 
also taken NSAIDs (any type or dosage) compared with no 
elevated risk when NSAID users were excluded. although no 
specific studies have identified a clear risk for increased GI 
bleeding when OTC NSAIDs are co-administered with oral 
corticosteroids, it may be prudent for health care providers 
to prescribe COX-2-specific NSAIDs or counsel patients to 
avoid OTC NSAIDs to reduce the potential risk for GI 
bleeding42. 
Drug interaction of NSAIDs 
NSAIDs are one of the most common causes of adverse drug 
reactions. As patient age and the number of medications 
increase, NSAIDs in the elderly should be prescribed with 
caution. NSAIDs concomitantly used with specific medication 
can alter the risk of gastrointestinal ulceration and/or 
bleeding. These drugs include selective serotonin reuptake 
inhibitors (SSRIs), corticosteroids, digitalis glycosides, 
diuretics, beta blockers, calcium antagonists, angiotensin 
converting enzyme, warfarin, clopidogrel, aspirin, and other 
anti-coagulants. Some specific NSAIDs were found to reduce 
renal clearance of Methotrexate, a commonly used 
medication for rheumatoid arthritis43. 
Conclusion 
Knowing about the mechanism of action, current guidelines, 
adverse drug reaction, and the pleiotropic effects of common 
drugs is important. NSAIDs are one of the most commonly 
prescribed drugs in the elderly. These medications should be 
prescribed for the shortest duration possible in the lowest 
effective dose, and with careful surveillance to monitor GI, 
renal, and cardiovascular toxicity. This is especially true for 
elderly patients who are very susceptible to the side effect 
profiles of NSAIDs. There is some evidence to support the 
role of NSAIDs in dementia prevention, improve muscle 
performance, improve urinary incontinence, and decrease 
the risk of some specific cancers. 
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